Application/Control No. Applicant(s)/Patent Under Reexamination 10/801,471 LYSSIKATOS ET AL. Notice of References Cited Examiner Art Unit Page 1 of 3 1625 R. James Balls U.S. PATENT DOCUMENTS **Document Number** Date Classification Name Country Code-Number-Kind Code MM-YYYY US-6,150,377 514/312 11-2000 Lys'sikatos et al. Α US-В US-С US-D US-Ε US-F US-G US-Н US-US-J US-Κ US-US-М FOREIGN PATENT DOCUMENTS Document Number Date Classification Country Name Country Code-Number-Kind Code MM-YYYY C07D 401/06 WO0012499A1 03-2000 PĆT Pfizer Products Inc. N 0 Ρ Q R S Т **NON-PATENT DOCUMENTS** Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages) Grever et al., The National Cancer Institute: Cancer Drug Discovery and Development Program, SEMINARS IN ONCOLOGY, U 19:6 622-638 (1992) Harry G. Brittain, POLYMORPHISM IN PHARMACEUTICAL SOLIDS (Marcel Dekker, Inc. 1999) LeCointe, Reach-Through Claims, INTERNATIONAL PHARMACEUTICAL (2002) (also available at: W http://www.bakerbotts.com/infocenter/publications/detail.aspx?id=bffe4a7d-5beb-4cf8-a189-15a5f190f0eb)

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).) Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Х

Silva, Reach Through Claims: Bust or Boon?, INTELLECTUAL PROPERTY UPDATE (available at:

http://www.dorsey.com/publications/legal_detail.aspx?FlashNavID=pubs_legal&pubid=170565003)

Notice of References Cited Application/Control No. 10/801,471 Examiner R. James Balls Applicant(s)/Patent Under Reexamination LYSSIKATOS ET AL. Page 2 of 3

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	Α	US-			
	В	US-			
	С	US-			
	D	US-			
	Ε	US-			
	F	US-			
	G	US-			
	н	US-			
	ı	US-			
	J	US-			
	к	US-			
	L	US-			
	М	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	0					
	Р					
	Q					
	R					
	s					
	Т					

NON-PATENT DOCUMENTS

*	Γ	Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	υ	Rodriguuez-Spong et al., General Principles of Pharmaceutical Solid Polymorphism: A supramolecular Perspective, ADV. DRUG DEL. REV., 56:241-274 (2004)
	V	Datta & Grant, Crystal Structures of Drugs: Advances in Determination, Prediction and Engineering, NATURE REVIEWS, 3:42-57 (2004)
	w	Rowland & Tozer, CLINICAL PHARMACOKINETICS 123 (Williams and Wilkins 1995)
	x	Silverman, THE ORGANIC CHEMISTRY OF DRUG DESIGN AND DRUG ACTION, (Academic Press, Inc.)

A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).) Dates in MM-YYYY format are publication dates. Classif ications may be US or foreign.

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	Α	US-			
	В	US-			
	С	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	Н	US-			
eri	ı	US-			
	J	US-			
	К	US-			
	L	US-			
	М	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	0					
	Р				A-12-	
	Q					
	R					
	s					
	Т					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	υ	Berge et al., Pharmaceutical Salts, J. PHARM. SCI. 66(1):1-19 (1977)
	v	
	w	
	x	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)

Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.